Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · USD

$61.3

-0.21 (-0.3%)· Recorded snapshot

Market cap	8.5B
Revenue (ttm)	67.7M
Net income (ttm)	-894M
EPS (ttm)	-$7.18
Shares out	139M
Volume	1,004,194
Beta	0.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 67.7M
Net income (ttm): -894M
EPS (ttm): -$7.18
Market cap: 8.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-46.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CYTK indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001061983
Company name	Cytokinetics, Incorporated
Country	United States
Country code	US
CUSIP number	23282W605
Earnings date	2026-11-04
Earnings time	amc
Employees	673
Employees change	175
Employees growth	35.14%
Enterprise value	$8.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1997
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2004-04-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US23282W6057
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2013-06-25
Last stock split type	Reverse
Market cap	$8.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$61.31
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CYTK
U.S. state	California
Website	https://www.cytokinetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.72%
EV/Sales	128.01x
FCF / EV yield	-6.7%
FCF yield	-6.91%
Forward EV/Sales	33.09x
Forward P/S	32.1x
P/S ratio	124.19x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-1,046.12%
Pretax margin	-1,321.12%
Profit per employee	$-1.3M
Revenue per employee	$100,550
ROA	-28.09%
ROA (5Y)	-25.94%
ROCE	-40.61%
ROIC	-46.78%
SBC / revenue	188.13%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	-21.07%
Revenue growth (Q)	-57.13%
Revenue growth (QoQ)	47.89%
Revenue growth 10Y	7.8%
Revenue growth 3Y	89.45%
Revenue growth 5Y	3.2%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-25.3M
Depreciation and amortization	$12.5M
EBIT	$-707.9M
EBITDA	$-695.4M
EPS	$-7.18
FCF per share	$-4.18
Financing cash flow	$1.2B
Free cash flow	$-580.7M
Free cash flow minus SBC	$-708M
Gross profit	$-337.4M
Investing cash flow	$-503.7M
Net borrowing	$315M
Net cash flow	$181.8M
Net income	$-894M
Operating cash flow minus SBC	$-682.8M
Operating income	$-707.9M
Revenue	$67.7M
Stock-based compensation	$127.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.25
Book value per share	$-1.25
Interest coverage	-5.67
Long-term assets	$716.1M
Long-term liabilities	$1.9B
Net cash (debt)	$-258.8M
Net cash / market cap	-3.08%
Piotroski F-Score	1
Property, plant and equipment	$151.8M
Shareholders' equity	$-173.5M
Tangible book value	$-173.5M
Tangible book value per share	$-1.25
Total assets	$1.9B
Total cash	$1.2B
Total debt	$1.4B
Total liabilities	$2.1B
WACC	6.56%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.04
Current assets	$1.2B
Current liabilities	$181.4M
Current ratio	6.66
Net working capital	$-59.5M
Quick ratio	6.56
Working capital	$1B
Working capital turnover	0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-5.07%
Dividend yield	0%
Shareholder yield	-5.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	587.83%
10Y return CAGR	21.27%
10Y total return	587.83%
150-day SMA	$72.25
15Y price change	772.63%
15Y return CAGR	15.54%
15Y total return	772.63%
1D price change	-0.34%
1M price change	-6.07%
1M total return	-6.07%
1W price change	-5.03%
1W total return	-5.03%
1Y price change	0.92%
1Y return CAGR	0.92%
1Y total return	0.92%
20-day SMA	$62.55
200-day SMA	$70.08
20Y price change	40.98%
20Y return CAGR	1.73%
20Y total return	40.98%
3M price change	-24.67%
3M total return	-24.67%
3Y price change	91.35%
3Y return CAGR	24.14%
3Y total return	91.35%
50-day SMA	$68.06
50-day SMA vs 200-day SMA	50under200
52-week high	$88.31
52-week high date	2026-06-30
52-week low	$58.05
52-week low date	2025-11-06
5Y price change	73.78%
5Y return CAGR	11.69%
5Y total return	73.78%
6M price change	-1.4%
6M total return	-1.4%
All-time high	$110.25
All-time high date	2024-01-08
All-time low	$3.05
All-time low date	2014-10-13
Average true range (ATR)	$2.01
Average volume	1.7M
Beta (1Y)	0.83
Beta (2Y)	0.87
Beta (5Y)	0.41
Change from 52-week high	-30.57%
Change from 52-week low	5.62%
Change from all-time high	-44.91%
Change from all-time low	1,891.31%
Change from open	0.74%
Day's gap	-1.07%
Dollar volume	$61.6M
High price	$61.31
Low price	$60.19
Monthly RSI	50.65
Open price	$60.86
Position in 52-week range	100%
Premarket change	0.13%
Premarket close	$61.52
Premarket price	$61.60
Premarket volume	29.4K
Previous close	$61.52
Price vs 150-day SMA	-15.94%
Price vs 20-day SMA	-2.9%
Price vs 200-day SMA	-13.34%
Price vs 50-day SMA	-10.77%
Relative volume	0.58
RSI	36.58
Sharpe ratio	0.13
Sharpe ratio (3Y)	0.54
Sharpe ratio (5Y)	0.4
Sortino ratio	0.35
Sortino ratio (3Y)	1.28
Sortino ratio (5Y)	0.84
Volume	1M
Weekly RSI	37.71
YTD price change	-4.41%
YTD total return	-4.41%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	138.5M
Float percentage	99.62%
Shares change (QoQ)	7.15%
Shares change (YoY)	5.07%
Shares held by insiders	0.34%
Shares held by institutions	116.99%
Shares outstanding	139M
Short % of float	13.45%
Short % of shares	13.4%
Short ratio	9.3 days

Deeper analysis on CYTK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CYTK report

Is a complete CYTK research report available?

No complete published report is available for Cytokinetics, Incorporated (CYTK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cytokinetics, Incorporated (CYTK)

Price

Financial snapshot

Fair-value bridge

Latest news · CYTK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CYTK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CYTK

Frequently asked questions